Pharma & Biotech - Page 19

AstraZeneca’s (AZN) first-in-class hypertension drug Baxfendy does not meet cost-effectiveness standards relative to its price, according to U.S. drug price watchdog ICER. The Institute for Clinical and Economic Review published a draft

Amy Niles, chief mission officer at the Patient Advocate Foundation, formerly known as the PAN Foundation, has outlined her vision for patient access reform in 2026. Niles warns that while several healthcare

Abbott (NYSE: ABT) and the Big Ten Conference are relaunching their “We Give Blood” campaign as the United States grapples with a severe national blood shortage. The American Red Cross has declared

TrumpRx has spent six months promoting lower drug prices, but critics argue the harder problem is whether patients can actually reach the pharmacy counter. Adam Colborn, vice president of government affairs at

Eli Lilly (LLY) delivered another extraordinary quarter of growth, posting a 48% year-over-year sales increase despite a slower-than-expected launch for its oral obesity drug Foundayo. Lilly reported Foundayo sales of $98 million

The strategies that guided bio/pharma commercialization for decades are being overhauled simultaneously, driven by sweeping changes across pricing, technology, and patient care. A fragmenting pricing environment, next-generation therapies straining existing infrastructure, and

Legend Biotech has reported its first quarter of company-wide profitability in its history, sending shares of the CAR-T therapy maker climbing around 6%. The milestone came alongside second-quarter 2026 results that delivered

Fleet managers across the pharmaceutical and logistics sectors are facing mounting pressure to identify inefficiencies that standard reporting tools consistently fail to surface. Many organisations invest heavily in fleet management software, yet

Eli Lilly (LLY) has filed lawsuits against six US companies it accuses of selling illegal versions of its experimental weight-loss drug retatrutide. The Indianapolis drugmaker is targeting California’s Aesthetic Envy Cosmetic Centers